TK-88

TK-88 is a preclinical small molecule drug being developed by **Tosk, Inc.** to mitigate the severe side effects associated with platinum-based chemotherapy agents, including **cisplatin**, **carboplatin**, and **oxaliplatin**. The drug specifically targets the prevention of **kidney toxicity** (nephrotoxicity), **peripheral neuropathy**, and **hearing loss** (ototoxicity), which are common dose-limiting toxicities in the treatment of **ovarian**, **breast**, **cervical**, and **lung cancers**. TK-88 was identified using Tosk's proprietary **Side Effect Fly** technology, a discovery platform that utilizes *Drosophila melanogaster* to screen for compounds that selectively block drug-induced toxicities without reducing the therapeutic efficacy of the primary treatment. As of the current reporting, the specific biological target of TK-88 remains undisclosed.